Trials / Completed
CompletedNCT01607892
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 286 (actual)
- Sponsor
- Karyopharm Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its effectiveness in treating cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KPT-330 |
Timeline
- Start date
- 2012-07-23
- Primary completion
- 2015-10-13
- Completion
- 2015-10-13
- First posted
- 2012-05-30
- Last updated
- 2023-01-26
- Results posted
- 2021-04-01
Locations
12 sites across 3 countries: United States, Canada, Denmark
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01607892. Inclusion in this directory is not an endorsement.